Navigation Links
How chemo kills tumors: research to reduce side effects
Date:8/6/2008

University of Manchester researchers are investigating exactly how chemotherapy drugs kill cancerous tumours in a bid to reduce side effects and test the effectiveness of safer new agents.

Dr Stephen Taylor and Karen Gascoigne at the University of Manchester's Faculty of Life Sciences have taken a new systematic approach to studying anti-mitotic drugs, which are used extensively for breast or ovarian cancer in the UK.

This class of drugs, which includes the agent taxol, has been used clinically for many years because they are highly effective. However, as in all chemotherapy, there are side effects. In the case of taxol these include peripheral neuropathies which can lead to permanent nerve damage and loss of sensation in fingers.

In addition little is known about how anti-mitotic drugs work, despite a lot of research on them, because many studies were population-based approaches that were indirect and led to vague and confusing interpretations.

Dr Taylor said: "To bypass the neurotoxicity, new anti-mitotics are being generated. Early clinical studies show that these drugs do not result in significant neurotoxicity. The big question now is whether they will have anti-tumour effects.

"To help determine this, we need to know which types of tumours are likely to be sensitive to these new agents, and which ones are likely to be resistant. This would allow clinicians to better design the clinical trials, i.e. you only recruit patients who are likely to respond. In addition, if the drugs show promise, then it would pave the way for patient stratification in the future, again allowing oncologists to identify which patients are likely to benefit from these drugs in advance of treatment.

"To predict which types of tumours are likely to respond, we first need to know how anti-mitotic drugs work, both the classical drugs and these new agents."

He and Ms Gascoigne, whose findings are published in the journal Canc
'/>"/>

Contact: Mikaela Sitford
Mikaela.Sitford@manchester.ac.uk
01-612-752-111
University of Manchester
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. TG2 identified as potential therapeutic target in chemo-resistant ovarian cancer
2. Mitochondrial cholesterol makes response to chemotherapy difficult in hepatic cancer
3. Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer
4. New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
5. Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors
6. A search for protection against chemotherapy cardiotoxicity
7. UC health news: molecular pathway may predict chemotherapy effectiveness
8. Food scientists confirm commercial product effectively kills bacteria in vegetable washwater
9. New UGA invention effectively kills foodborne pathogens in minutes
10. Mounting evidence shows red wine antioxidant kills cancer
11. New decontamination system kills anthrax rapidly without lingering effects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2015)... , Feb. 12, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62/113114 for DISTRIBUTED METHOD AND ... The patent further establishes NXT-ID,s position in the ... property portfolio the ability for multiple devices to collaborate ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America recently ... for carbon nanotube (CNT) macrostructures, including sheets, yarns and ... (UTD). Leveraging the vast industrial resources of ... Japan , Lintec of America is forming the ... TX , focusing on scaling up the manufacturing ...
(Date:2/5/2015)... Epic Sciences , a precision diagnostics company dedicated to improving ... , Ph.D., president and CEO, is scheduled to present at ... Valley, which is taking place at the Computer History Museum ... 26-28, 2015. Dr. Prahalad will give a ... Epic Sciences was a finalist in the PMWC,s Most Promising ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... , LAS VEGAS , April 27 In its third ... open to a more inclusive pool of contestants and takes place three times ... Championship) invites any company with tea inventory in North America to ... harvests of hot tea, as well as iced tea. , ...
... April 27 From international jetsetter to model to entrepreneur, ... resume as she unveils her debut collection for QVC. The Slovenian beauty is scheduled ... PM (ET) to debut the Melania™ Timepieces & Fashion Jewelry line ... , , ...
... with a volume equivalent to 40 Amazon Rivers has been ... in the Indian Ocean sector of the Southern Ocean, 4200 ... Nature Geoscience , the researchers described the current more ... important pathway in a global network of ocean currents that ...
Cached Biology News:World Tea Expo Throws Open Door to Tea Championship 2Melania Trump Takes 'Time' To Shine With New QVC(R) Collection 2Melania Trump Takes 'Time' To Shine With New QVC(R) Collection 3Melania Trump Takes 'Time' To Shine With New QVC(R) Collection 4Massive Southern Ocean current discovered 2
(Date:3/3/2015)... Calif. , March 3, 2015 AtheroNova Inc. ... AtheroNova Operations, Inc., filed voluntary petitions under Chapter 11 of ... District of California , Santa ... 2015. The Company,s Chapter 11 cases are expected to be ... including a Bankruptcy Court supervised asset sale process, for all ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Becht ... today that it has acquired The CECON Group, ... the transaction were not announced. , Becht Engineering ... the energy sector including oil and gas production, ... fossil and nuclear power sectors. The company has ...
(Date:3/3/2015)... CAMBRIDGE, Mass. (PRWEB) March 03, 2015 ... driven by Semantic Web technology, today announced that it ... ‘100 Companies That Matter in Knowledge Management.’ , ... select group of colleagues, analysts and system integrators who ... and delivery of the right information to the right ...
(Date:3/3/2015)... Mar. 03, 2015 Research and Markets ... PharmaBiotech,s new report "RNAi - Technologies, Markets and ... Because of its ability to silence any gene once ... the research tool to discriminate gene function. After the ... designed to target every gene in the genome and ...
Breaking Biology Technology:AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 4Cambridge Semantics Named to KMWorld’s 2015 ‘100 Companies That Matter in Knowledge Management’ 2Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 2Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 3
... ... ... ... ...
... ... to bring more attention to the need for finding more treatments for diseases which affect ... ... to the urgent need of finding more treatments for rare diseases by partnering with the ...
... ... ... , , ... IGEN Networks Corp. (IGEN: OTCBB) , ...
Cached Biology Technology:Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 2Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 3Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 4Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 5Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 6Peer-reviewed Articles Further Define Clusterin and the Role of a Clusterin Inhibitor, OGX-011, for the Treatment of Cancer 7Raising Awareness of Rare Diseases, Anson Group Announces Sponsorship of Rare Disease Day 2IGEN Networks appoints directors and provides business update 2IGEN Networks appoints directors and provides business update 3
... System - dUTP with CyScribe GFX ... generation and purification of Cy3- and ... for complete cDNA labeling and purification.Flexible ... for performing labeling reactions with either ...
Collected from sexually mature, mixed sex, mixed breed dogs. Serum from specific breeds available by request....
Homo sapiens toll interacting protein Antigen: Recombinant Protein...
... 1. 1000 V, 400 mA, 100 ... constant power modes.Single-unit increments in settings ... and recalls three protocols.Outstanding choice for ... Multiphor II or GenePhor systems. Category: ...
Biology Products: